
KD Finechem Coolant Innovations for Sustainable Performance
Supplied by an entity that has paid the news provider for its placement; not impartial journalism.
As technology continues to soar to new heights, one thing remains a constant: heat management. No system can perfectly utilize 100 percent of the energy it generates, and cooling is an enormous economic and safety challenge for everything from automobiles to IT server infrastructure. Furthermore, cooling is not exempt from the green transformation sweeping through industries. Future solutions require innovation, and Korea's KD Finechem is leveraging its decades of experience developing and supplying coolant in the automotive sector to tackle modern problems.
Founded in 1973, KD Finechem has been a major supplier of coolant to Korean automakers and is presently leading the industry in developing coolants suitable for electrical systems, such as EVs and IT infrastructure, and environmentally conscious coolants. CEO Hyun Jin Park says that the industry has shifted toward greener vehicles, and demand for specialized coolant is increasing. "This change created new opportunities for us because traditional ICE vehicle coolants were a long-established market dominated by legacy suppliers," he explains. KD Finechem entered a competitive market where major automakers already had established suppliers. However, with the rise of EVs and FCEVs, major players are now open to exploring new partnerships with companies with specialized cooling solutions expertise.
Hyun Jin Park, CEO, KD Finechem Co., Ltd. Credit: Courtesy of KD Finechem Co., Ltd.
Hyun Jin Park, CEO, KD Finechem Co., Ltd. Credit: Courtesy of KD Finechem Co., Ltd.
By working closely with major Korean automakers, KD Finechem developed the first EV-specific coolant, which established the company's credibility with other OEMs. Park says that new industries require agility to innovate. "While the EV market is growing, it is still relatively small from the perspective of major petrochemical companies," he states. As a privately owned company, KD Finechem can react quickly and has the flexibility to invest in emerging markets early, giving it the first mover advantage. "This is why we can dedicate more resources to R&D, particularly in areas like EV batteries and even data centers," Park explains.
The company's core concepts are safety and reliability, and its efforts have been centered around direct collaboration with OEMs and real-life applications. "Our expertise extends beyond coolant formulation—it's also about optimizing the entire system," Park says. For FCEVs, the company has developed a noncorrosive coolant that can be used with more economical materials than titanium. Coolant for ICE vehicles can short-circuit an EV battery, leading to a fire, so it developed a nonconductive coolant, which it is currently working to extend its lifespan. The company also looks to source ethylene glycol, which is currently derived from petrochemicals, from eco-friendly sources. It is working with a company that has successfully produced ethylene glycol, with positive initial tests. Park describes the company's customers' priorities as reliability, safety and customized compatibility with their high-value infrastructure. "Our ability to develop highly specialized solutions, even for low-volume applications, gives us a unique edge in markets that large players tend to overlook," he says.
KD's permeable fuel-cell coolant dye. Credit: Courtesy of KD Finechem Co., Ltd.
KD's permeable fuel-cell coolant dye. Credit: Courtesy of KD Finechem Co., Ltd.
This agility is evident in KD Finechem's adaptability. Park explains that the company can easily adjust without significant infrastructure expansion. Because all coolants share monoethylene glycol as a base material, transitioning to new water-soluble formulations is seamless. "This flexibility gives us a competitive edge, enabling us to scale production efficiently while minimizing additional investment," Park says. The company has tailored its coolants not only for EVs and FCEVs but also for batteries, energy storage systems (ESS), data centers and high-speed charging cables. With AI data centers increasingly prioritizing lower operational costs and greater efficiency, KD Finechem is well positioned to pivot and meet the demands of these rapidly growing sectors.
As the world continues to rely on technology, Park only sees KD Finechem's global opportunities growing. "Our customers include any industry that deals with heat management," he states. Automotive and IT remain core targets in Europe and the United States, where the company already has local production facilities. However, liquid cooling is growing in both personal computing and, theoretically, even aerospace. Park summarizes this reality, "In an ideal system, no heat would be generated because all energy would be perfectly utilized. But until that becomes reality, thermal management will remain essential."
Global Network. Credit: Courtesy of KD Finechem Co., Ltd.
Global Network. Credit: Courtesy of KD Finechem Co., Ltd.
For more details, explore the website at: https://www.kdfinechem.com/en/
This report has been paid for by a third party. The views and opinions expressed are not those of Newsweek and are not an endorsement of the products, services or persons mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Verge
5 hours ago
- The Verge
It's the closest we're likely to get to a global release for
Xiaomi's SU7 Ultra is launching outside China... in Gran Turismo. Xiaomi's souped up EV, which last year set a record lap time for a four-door car at the Nürburgring, albeit using a stripped-out prototype to do so. There's no release date just yet for the car's addition to Gran Turismo 7 though.
Yahoo
17 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme(the tradename of Merck & Co., Inc., Rahway, NJ, USA)is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy; OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy; OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech( a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
18 hours ago
- Yahoo
Lucid signs US graphite supply deal for EV batteries
This story was originally published on Supply Chain Dive. To receive daily news and insights, subscribe to our free daily Supply Chain Dive newsletter. Lucid Group has signed a second agreement with Graphite One for U.S.-sourced materials needed for lithium-ion batteries as the electric car maker seeks to strengthen its domestic supply chain, according to a June 4 press release. The latest agreement will provide Lucid and its battery cell suppliers with natural graphite from the Graphite Creek deposit north of Nome, Alaska, where Graphite One expects to begin production in 2028, per the release. The deal complements a 2024 pact in which Graphite One agreed to provide Lucid and its battery cell suppliers with graphite processed for use in battery anodes, starting in 2028, the release said. The active anode material (AAM) would come from Graphite One's planned plant in Warren, Ohio. Lucid has increased U.S.-based battery-electric-vehicle production as part of its strategy for weathering tariff uncertainty. Executives have highlighted the company's efforts to localize critical supplies, including the transition to Panasonic's Kansas battery facility and the sourcing of domestic graphite through partnerships with Graphite One and Syrah Resources. Beginning next year, Syrah will supply AAM from its production facility in Vidalia, Louisiana, under a three-year deal with Lucid, per the release. "A supply chain of critical materials within the United States drives our nation's economy, increases our independence against outside factors or market dynamics, and supports our efforts to reduce the carbon footprint of our vehicles," Lucid interim CEO Marc Winterhoff said in the release. Establishing supplier networks to build EV batteries has been a trend encompassing both traditional automakers and EV-only makers, such as Lucid. For example, Nissan Motor Corp and SK On signed a battery deal in March. The previous deal between Lucid and Graphite One is a non-binding supply agreement, pending Graphite One's commencement of AAM graphite production at the Ohio facility, according to the Canadian company's annual Management's Discussion and Analysis document, filed in April. The plant is Graphite One's first AAM factory, CEO Anthony Huston told Supply Chain Dive. If successful, the Lucid and Graphite One partnership would establish a U.S. source of graphite materials for EV batteries for the carmaker. However, Hunan Chenyu Fuji New Energy Technology, an AAM manufacturer based in Changsha, China, would play a critical role in supporting the partnership. Graphite One signed a technology licensing agreement and a consulting agreement with Chenyu last October, according to the MD&A document. Chenyu agreed to assist in the design, construction and operation of the Ohio facility. Additionally, Chenyu would receive quarterly royalties for its technology used in AAM manufacturing. Graphite One turned to Chenyu for the technology because it doesn't exist in the U.S., Huston said. 'There's no technology in the United States,' Huston said. 'And the reason why is because we haven't had it [graphite production] for 34 years. Once you stop producing something, you lose the ability to have the know-how, and the understanding, and the actual processing side that surrounds it.' Editor's note: This story has been updated to include comments from Graphite One CEO Anthony Huston Recommended Reading Automotive supply chains can benefit from sourcing alliances. Here's why. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data